Efficacy News and Research

RSS

Breakthrough improves effectiveness of tuberculosis vaccine

A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine 's Advance Online Publication March 1.

8 Mar 2009

Emerging therapies could ease symptoms of Atopic dermatitis

Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children.

5 Mar 2009

Hendra and Nipah viruses shown to be susceptible to chloroquine

Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology.

5 Mar 2009

Laser technology shown to effectively clear acne

From the removal of childhood birthmarks to skin rejuvenation, laser technology has become a mainstay in dermatology.

5 Mar 2009

Experimental microbicide containing natural compound provides protection in monkeys against simian version of HIV

An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.

5 Mar 2009

Penis extender shown to increase length by third over six months

Men who wore a penile extender every day for six months were able to increase the flaccid length of their penis by up to 32% and their erectile function by up to 36%, according to an independent clinical study published in the March issue of BJU International.

5 Mar 2009

Patented inventions double at University at Buffalo

An antibody with the potential to stop breast cancer in its path. A nanoparticle that can address a side effect of the treatment that hemophiliacs cannot live without. A "quantum dot" with the potential to treat cancer or harvest the power of the sun. An air purifier that kills the world's nastiest toxins.

5 Mar 2009

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Mar 2009

Cordex Pharma files ATPace formulation patent

Cordex Pharma, Inc. has announced today that it has filed a formulation patent covering its lead product, ATPace.

4 Mar 2009

Opioid antagonists help pain management

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

3 Mar 2009

Trial looks at telmisartan in treating non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

3 Mar 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Aerovance starts trial of Aerovant for uncontrolled asthma

Aerovance Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

3 Mar 2009

New optical technology shows promise in detecting pancreatic cancer

Optical technology developed by a Northwestern University professor of biomedical engineering has been shown to be effective in detecting the presence of pancreatic cancer through analysis of neighboring tissue in the duodenum, according to clinical trial results published in the journal Disease Markers.

2 Mar 2009

Endo Pharmaceuticals licenses investigational drug axomadol from Grunenthal

Endo Pharmaceuticals announced that it has licensed from Grunenthal the exclusive rights to develop and market the investigational drug axomadol in the United States and Canada.

2 Mar 2009

FDA takes action against KV Pharmaceutical Company

The FDA announced a Consent Decree of permanent injunction filed March 2, 2009, enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers from making and distributing adulterated and unapproved drugs.

2 Mar 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009

New discovery improves efficacy of current tuberculosis vaccine

A new article appearing in the March 2009 issue of the Journal of Leukocyte Biology may lead to improvements in the efficacy of the current tuberculosis vaccine.

26 Feb 2009

Experimental animal vaccine may protect humans from Ebola

Protection against Ebola, one of the world's deadliest viruses, can be achieved by a vaccine produced in insect cells, raising prospects for developing an effective vaccine for humans, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

26 Feb 2009

United States files complaint against Forest Labs for allegedly violating the false claims act with Celexa and Lexapro

A Complaint was unsealed today in U.S. District Court in Massachusetts against a New York pharmaceutical company for alleged False Claims Act violations arising from the company's marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying kickbacks to induce physicians to prescribe the drugs.

25 Feb 2009